MINT-LOSARTAN TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

LOSARTAN POTASSIUM

Prieinama:

MINT PHARMACEUTICALS INC

ATC kodas:

C09CA01

INN (Tarptautinis Pavadinimas):

LOSARTAN

Dozė:

25MG

Vaisto forma:

TABLET

Sudėtis:

LOSARTAN POTASSIUM 25MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30/100/500

Recepto tipas:

Prescription

Gydymo sritis:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produkto santrauka:

Active ingredient group (AIG) number: 0127971001; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2015-03-03

Prekės savybės

MINT-LOSARTAN
_MINT-LOSARTAN(losartan _
_potassium) _
_Page 1 of 44_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-LOSARTAN
Losartan Potassium Tablets
Tablets, 25 mg, 50 mg and 100 mg, Oral
House Standard
Angiotensin II Receptor Antagonist
MINT PHARMACEUTICALS INC.
6575 Davand Drive
Mississauga, ON Canada L5T 2M3
Date of Initial Authorization:
May 9, 2013
Date of Revision:
April 18, 2023
Submission Control Number: 269236
_MINT-LOSARTAN_
_ _
_(losartan potassium) _
_Page 2 of 44_
_ _
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................................................
4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
..............................................................................................................................
4
1.2
Geriatrics
..............................................................................................................................
4
2
CONTRAINDICATIONS
.............................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.........................................................................
5
4
DOSAGE AND ADMINISTRATION
.............................................................................................
5
4.1
Dosing Considerations
..........................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................